SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-113239
Filing Date
2020-10-08
Accepted
2020-10-08 07:16:30
Documents
12
Period of Report
2020-10-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2032537-2_8k.htm   iXBRL 8-K 28518
  Complete submission text file 0001104659-20-113239.txt   207357

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA axgt-20201005.xsd EX-101.SCH 3239
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE axgt-20201005_lab.xml EX-101.LAB 34591
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE axgt-20201005_pre.xml EX-101.PRE 22708
5 EXTRACTED XBRL INSTANCE DOCUMENT tm2032537-2_8k_htm.xml XML 3818
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37418 | Film No.: 201230104
SIC: 2834 Pharmaceutical Preparations